Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer

Completed · Phase 1

Conditions studied: Colorectal Cancer

In brief

RATIONALE: Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances, such as radioactive iodine, to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody in treating patients with advanced colorectal cancer.

Key facts

Study ID

NCT00003360

Run by

Memorial Sloan Kettering Cancer Center

People needed

24

Starts

1998-04-01

Last updated by the study team

2013-01-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.